An Open Label, Single Arm Pilot Study of Oncosil, Administered to Subjects with Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination with Gemcitabine or Gemcitabine+Nab-Paclitaxel Chemotherapies
MD Anderson Study Status
To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy FDA regulatory requirements. The clinical investigation will be conducted at approximately 5 sites in the United States involving 20 patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Unresectable Locally Advanced Pancreatic Carcinoma
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.